Cocrystal Pharma, Inc.
COCPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $2.0M |
| Operating income | −$9.0M | −$17.9M | −$18.6M | −$38.8M | −$14.2M | −$9.6M |
| Net income | −$8.8M | −$17.5M | −$18.0M | −$38.8M | −$14.2M | −$9.6M |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M | $54.2M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M | $1.7M |
| Equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M | $52.5M |
| EPS (diluted) | $-0.78 | $-1.72 | $-1.87 | $-4.77 | $-0.16 | — |
| Shares out. | 10.2M | 10.2M | 8.1M | 97.5M | 71.5M | 52.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −139.5%
- Return on assets
- −90.9%
- Return on capital (ROCE)
- −120.2%
- Liabilities / assets
- 34.8%
- Debt / equity
- 0.53×
- Book value / share
- $0.62
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -115.15distress
- Accruals / assets
- −6.6%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 19, 2019
- NT 10-Kmissed a reporting deadline ↗Mar 19, 2018
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2017
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2014
- NT 10-Q/Amissed a reporting deadline ↗Nov 13, 2013
- NT 10-Qmissed a reporting deadline ↗Nov 12, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Frost Phillip Md Et AlActivist (13D)Oct 30, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Frost Phillip Md Et AlDirector | Feb 24, 2026 | Buy | 20,000 | $1.00 |
| Frost Phillip Md Et AlDirector | Feb 6, 2026 | Buy | 50,000 | $0.95 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 192,682 | 1.4 | -67.1% |
| Apr 30, 2026 | 586,422 | 3.1 | -40.7% |
| Apr 15, 2026 | 988,346 | 1.0 | +563.7% |
| Mar 31, 2026 | 148,911 | 3.0 | -30.5% |
| Mar 13, 2026 | 214,196 | 6.2 | -18.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 26, 2026
- Regulation FD disclosureApr 30, 2026
- Regulation FD disclosureApr 2, 2026
- Results of operationsMar 31, 2026
- Director / officer changeMar 13, 2026
- Regulation FD disclosureMar 9, 2026
- Regulation FD disclosureFeb 19, 2026
- Director / officer changeJan 15, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.